Tags

Type your tag names separated by a space and hit enter

Current surgical management of Zollinger-Ellison syndrome (ZES) in patients without multiple endocrine neoplasia-type 1 (MEN1).
Surg Oncol. 2003 Aug; 12(2):145-51.SO

Abstract

The role of surgery in the management of patients with sporadic (not part of multiple endocrine neoplasia type 1) Zollinger-Ellison syndrome (ZES) is controversial. In this setting, 60-90% of gastrinomas are malignant and medical therapy can control the gastric acid hypersecretion in virtually every patient. Therefore, the progression of tumor is the major determinant of survival. Surgery will cure approximately one-third of patients with sporadic ZES. It will decrease the development of liver metastases and may improve survival. Somatostatin receptor scintigraphy is the best preoperative localization study. Its results are as good as all other imaging studies combined. Operative techniques should always include duodenotomy (opening the duodenum) and meticulous dissection of lymph nodes in the gastrinoma triangle, because duodenal primary tumors are often missed and lymph node primary tumors or metastases are common. Postoperative evaluation should include secretin test because it is the most sensitive method to document cure and detect tumor recurrence.

Authors+Show Affiliations

Department of Surgery, University of California San Francisco, 533 Parnassus Avenue, Room U-372, San Francisco, CA 94143-0790, USA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

12946485

Citation

Norton, Jeffrey A., and Robert T. Jensen. "Current Surgical Management of Zollinger-Ellison Syndrome (ZES) in Patients Without Multiple Endocrine Neoplasia-type 1 (MEN1)." Surgical Oncology, vol. 12, no. 2, 2003, pp. 145-51.
Norton JA, Jensen RT. Current surgical management of Zollinger-Ellison syndrome (ZES) in patients without multiple endocrine neoplasia-type 1 (MEN1). Surg Oncol. 2003;12(2):145-51.
Norton, J. A., & Jensen, R. T. (2003). Current surgical management of Zollinger-Ellison syndrome (ZES) in patients without multiple endocrine neoplasia-type 1 (MEN1). Surgical Oncology, 12(2), 145-51.
Norton JA, Jensen RT. Current Surgical Management of Zollinger-Ellison Syndrome (ZES) in Patients Without Multiple Endocrine Neoplasia-type 1 (MEN1). Surg Oncol. 2003;12(2):145-51. PubMed PMID: 12946485.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current surgical management of Zollinger-Ellison syndrome (ZES) in patients without multiple endocrine neoplasia-type 1 (MEN1). AU - Norton,Jeffrey A, AU - Jensen,Robert T, PY - 2003/8/30/pubmed PY - 2004/2/6/medline PY - 2003/8/30/entrez SP - 145 EP - 51 JF - Surgical oncology JO - Surg Oncol VL - 12 IS - 2 N2 - The role of surgery in the management of patients with sporadic (not part of multiple endocrine neoplasia type 1) Zollinger-Ellison syndrome (ZES) is controversial. In this setting, 60-90% of gastrinomas are malignant and medical therapy can control the gastric acid hypersecretion in virtually every patient. Therefore, the progression of tumor is the major determinant of survival. Surgery will cure approximately one-third of patients with sporadic ZES. It will decrease the development of liver metastases and may improve survival. Somatostatin receptor scintigraphy is the best preoperative localization study. Its results are as good as all other imaging studies combined. Operative techniques should always include duodenotomy (opening the duodenum) and meticulous dissection of lymph nodes in the gastrinoma triangle, because duodenal primary tumors are often missed and lymph node primary tumors or metastases are common. Postoperative evaluation should include secretin test because it is the most sensitive method to document cure and detect tumor recurrence. SN - 0960-7404 UR - https://www.unboundmedicine.com/medline/citation/12946485/Current_surgical_management_of_Zollinger_Ellison_syndrome__ZES__in_patients_without_multiple_endocrine_neoplasia_type_1__MEN1__ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0960740403000355 DB - PRIME DP - Unbound Medicine ER -